We have developed C-STEMTM : a proprietary technology for the mass-production of cell therapies.
A series of proprietary cell therapy programs for co-development or licensing
TreeFrog Therapeutics receives additional €3M non-dilutive funding to mass-produce clinical-grade cell therapies by 2021 Company awarded close to €3M ($3.3M) in public grants only five months after Series A round of €7M ($7.8M) Bordeaux, France, September 5, 2019 – TreeFrog Therapeutics, an expert......
05 September, 2019 News Press
TreeFrog Therapeutics has developed C-Stem™ : a proprietary technology platform for the mass-production of iPSc-based cell therapies. C-Stem™ secures cell quality (100% genomic integrity), volumes (x100 cell amplification per week) and dramatically reduces cell therapy costs (by 10 today, by 100 tomorrow). Learn about C-Stem...
04 September, 2019 Video
TreeFrog will be in Japan from the 10th to 21th of September 2019 to meet key academic and industry players ! This cell therapy roadtrip, organized with the help of Business France, will be marked by our participation to Cell Therapy Word Asia 2019 on Sept 18-19......
03 September, 2019 Events NewsI am test text for Image with text shortcode. |
TreeFrog Therapeutics is a French stem cell company aiming at supporting the advent and industrial development of stem cell therapies.